Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empiric versus preemptive antifungal therapy in febrile neutropenic onco-hematologic adults
2008-008382-35Phase 4Active
- Sponsor
- Azienda Ospedaliera di Perugia
- Start
- May 2009
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amphotericin b and caspofungin in invasive mycoses and opportunistic mycoses (2 arms), sponsored by Azienda Ospedaliera di Perugia. Primary endpoints: Number of patients undergoing antifungal therapy, Number of documented invasive fungal infections and 2 more. Started May 2009; status: active.
02
Drugs
amphotericin bcaspofungin
03
Conditions
invasive mycosesopportunistic mycoses
Beyond the preview
Go deeper on 2008-008382-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008382-35.